drugset / Trial / NCT00354224

Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer

NCT00354224 ↗

Phase 2 Terminated 10 enrolled Medical University of South Carolina
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving capecitabine together with oxaliplatin works in treating patients with locally advanced, unresectable, or metastatic stomach cancer.

Timeline

Start
2005-01
Primary completion
2008-08
Completion
2008-08

Outcome

Outcome not reported

Stopped (Enrollment): “due to low accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 850 mg/m2 Oral
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous

Indications